OncoMatch/Clinical Trials/NCT06493760

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

Is NCT06493760 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for metastatic colorectal cancer.

Phase 2RecruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06493760Data as of May 2026

Treatment: SSGJ-707 · Bevacizumab · Oxaliplatin · Capecitabine · Calcium Folinate · 5-fluorouracil — This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify